RRC ID 52809
Author Hashimoto A, Hagiwara D, Watanabe A, Yahiro M, Yikelamu A, Yaguchi T, Kamei K.
Title Drug Sensitivity and Resistance Mechanism in Aspergillus Section Nigri Strains from Japan.
Journal Antimicrob Agents Chemother
Abstract Aspergillus niger and its related species, known as Aspergillus section Nigri, are ubiquitously distributed across the globe and are often isolated from clinical specimens. In Japan, Aspergillus section Nigri is second most often isolated from clinical specimens following Aspergillus fumigatus We determined the species of Aspergillus section Nigri isolated in Japan by DNA sequencing of partial β-tubulin genes and investigated drug susceptibility by the CLSI M38-A2 method. The collection contained 20 Aspergillus niger, 59 Aspergillus welwitschiae, and 39 Aspergillus tubingensis strains. Drug susceptibility testing revealed 30 to 55% of A. niger, 6.8 to 18.6% of A. welwitschiae, and 79.5 to 89.7% of A. tubingensis isolates to be less susceptible (so-called resistant) to itraconazole (ITC) and/or voriconazole (VRC) according to the epidemiologic cutoff values (ECVs) proposed for A. niger previously. MIC distributions of ITC or VRC showed no remarkable differences between clinical and environmental isolates. When the cyp51A sequences were compared between susceptible and resistant strains, 18 amino acid mutations were specific for resistant isolates of A. niger and A. tubingensis; however, none of them were confirmed to be associated with azole resistance. Three nonrelated A. welwitschiae isolates possessed a partial deletion in cyp51A, likely attributable to being more susceptible to azoles than other isolates. One of five ITC-resistant A. tubingensis isolates showed higher expression of cyp51A than did susceptible strains. Our results show that cyp51A point mutations may have no association with azole resistance but that in some cases the overexpression of cyp51A may lead to the azole resistance in these species.
Volume 61(8)
Published 2017-8-1
DOI 10.1128/AAC.02583-16
PII AAC.02583-16
PMID 28607016
PMC PMC5527657
MeSH Amphotericin B / pharmacology Antifungal Agents / pharmacology* Aspergillosis / drug therapy* Aspergillosis / microbiology Aspergillus niger / classification Aspergillus niger / drug effects* Aspergillus niger / genetics* Aspergillus niger / isolation & purification Cytochrome P-450 Enzyme System / genetics* Drug Resistance, Multiple, Fungal / genetics* Echinocandins / pharmacology Fungal Proteins / genetics* Humans Itraconazole / pharmacology Japan Lipopeptides / pharmacology Micafungin Microbial Sensitivity Tests Voriconazole / pharmacology
IF 4.904
Times Cited 16
Pathogenic eukaryotic microorganisms 病原真菌:IFM 54886, IFM 64130, IFM 56815, IFM62857, IFM 55763, IFM 64128, IFM63887, IFM56186, IFM62144, IFM 62615, IFM 63604, IFM 6897, IFM 63883, IFM 63885, IFM 63886, IFM54680, IFM 54683, IFM 55705, IFM 62929, IFM 64121, IFM 60653, IFM 63877, IFM 63876